EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudie

Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis

Federico Piñero iD, Margarita Anders iD, Carla Bermudez iD, Diego Arufe iD, Adriana Varón, Ana Palazzo iD, Jorge Rodriguez, Oscar Beltrán, Daniela Simian iD, Leonardo Gomes da Fonseca iD, Ezequiel Ridruejo iD, Norberto Tamagnone und 10 weitere

Liver International · 2025

DOI: 10.1111/liv.70092 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Liver International, 2025. Verfasst von Federico Piñero und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Austral, Pilar, Argentina. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The survival outcomes associated with hepatic recompensation in patients with advanced hepatocellular carcinoma (HCC) treated with first‐line systemic therapies remain unclear. We compared survival from the initiation of first‐line systemic treatments for advanced HCC among patients with compensated, decompensated, and recompensated cirrhosis.

Methods

A Latin American multicenter, prospective cohort study was conducted from 2018 to 2024, involving patients with HCC and Child‐Pugh class A or B who received systemic therapy. At the time of first‐line therapy, patients with cirrhosis were categorised as compensated (never decompensated), decompensated, or recompensated. Cox proportional hazards models were estimated.

Results

Among 306 patients receiving first‐line systemic therapy (sorafenib: 60.5%, atezolizumab + bevacizumab: 29.7%, lenvatinib: 9.1%), 240 had cirrhosis, with 30.4% having a history of hepatic decompensation. Of these, 57.5% (95% CI 45.4%–69.0%) achieved hepatic recompensation over a median period of 12 months. At the time of first‐line therapy, 69.6% were compensated, 17.5% recompensated, and 12.9% decompensated. Metabolic‐associated steatotic liver disease (MASLD) was the most common underlying aetiology in the recompensated group. Median survival was significantly shorter in the decompensated group (8.6 months) compared to the compensated group (17.2 months) [aHR 1.91 (95% CI 1.04–3.5); p = 0.03], without a significant difference between the recompensated and compensated groups [aHR 1.28 (95% CI 0.79–2.1); p = 0.31]. Tumour progression was the primary reason for treatment discontinuation, and similar access to second‐line therapies was observed between the compensated and recompensated groups.

Conclusion

Patients with cirrhosis and advanced HCC who achieved hepatic recompensation might benefit from systemic therapies after a cautious observation period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver CirrhosisLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBevacizumabPhenylurea CompoundsProportional Hazards ModelsProspective StudiesQuinolinesSorafenib

Stichwörter der Autor:innen

cirrhosisliver canceroutcomesprognosisreal worldrecompensation

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabBevacizumablenvatinibPhenylurea CompoundsQuinolinesSorafenib

Autor:innen und Institutionen

  • Hospital Universitario Austral, Pilar, Argentina.
  • Hospital Alemán, Buenos Aires, Argentina.
  • Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Sanatorio Sagrado Corazón, Buenos Aires, Argentina.
  • Fundación Cardioinfantil, Bogotá, Colombia.
  • Hospital Padilla, Tucumán, Argentina.

ORCID-Profile: Federico Piñero, Margarita Anders, Carla Bermudez, Diego Arufe, Ana Palazzo, Daniela Simian, Leonardo Gomes da Fonseca, Ezequiel Ridruejo, Hugo Cheinquer, Diana Bejarano, Josefina Pages, Jaime Poniachik, Sebastián Marciano, Virginia Reggiardo, Marcelo Silva, Manuel Mendizabal

Zitieren

APA

Piñero, F., Anders, M., Bermudez, C., Arufe, D., Varón, A., Palazzo, A., Rodriguez, J., Beltrán, O., Simian, D., da Fonseca, L. G., Ridruejo, E., Tamagnone, N., Cheinquer, H., Bejarano, D., Marín, J. I., Orozco, F., Pages, J., Poniachik, J., Marciano, S., …, & Mendizabal, M. (2025). Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis. Liver International. https://doi.org/10.1111/liv.70092

Vancouver

Piñero F, Anders M, Bermudez C, Arufe D, Varón A, Palazzo A, et al. Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis. Liver International. 2025. doi:10.1111/liv.70092

BibTeX
@article{Piero2025,
  author = {Piñero, Federico and Anders, Margarita and Bermudez, Carla and Arufe, Diego and Varón, Adriana and Palazzo, Ana and Rodriguez, Jorge and Beltrán, Oscar and Simian, Daniela and da Fonseca, Leonardo Gomes and Ridruejo, Ezequiel and Tamagnone, Norberto and Cheinquer, Hugo and Bejarano, Diana and Marín, Juan Ignacio and Orozco, Federico and Pages, Josefina and Poniachik, Jaime and Marciano, Sebastián and Reggiardo, Virginia and Silva, Marcelo and Mendizabal, Manuel},
  title = {Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70092}
}
Kostenlos starten →